Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Purple Biotech stock

Own Purple Biotech stock in just a few minutes.

Purple Biotech Ltd is a biotechnology business based in the US. Purple Biotech shares (PPBT) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Purple Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PPBT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Purple Biotech share price

Use our graph to track the performance of PPBT stocks over time.

Purple Biotech shares at a glance

Information last updated 2021-03-10.
52-week range$0.22 - $7.25
50-day moving average $4.94
200-day moving average $4.39
Wall St. target price$25.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Purple Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Purple Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Purple Biotech financials

Revenue TTM $1 million
Gross profit TTM $1 million
Return on assets TTM -16%
Return on equity TTM -61.97%
Profit margin 0%
Book value N/A
Market capitalisation $72.8 million

TTM: trailing 12 months

Shorting Purple Biotech shares

There are currently 314,116 Purple Biotech shares held short by investors – that's known as Purple Biotech's "short interest". This figure is 11% down from 353,122 last month.

There are a few different ways that this level of interest in shorting Purple Biotech shares can be evaluated.

Purple Biotech's "short interest ratio" (SIR)

Purple Biotech's "short interest ratio" (SIR) is the quantity of Purple Biotech shares currently shorted divided by the average quantity of Purple Biotech shares traded daily (recently around 1.4 million). Purple Biotech's SIR currently stands at 0.22. In other words for every 100,000 Purple Biotech shares traded daily on the market, roughly 220 shares are currently held short.

However Purple Biotech's short interest can also be evaluated against the total number of Purple Biotech shares, or, against the total number of tradable Purple Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Purple Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Purple Biotech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Purple Biotech shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Purple Biotech.

Find out more about how you can short Purple Biotech stock.

Purple Biotech share dividends

We're not expecting Purple Biotech to pay a dividend over the next 12 months.

Purple Biotech share price volatility

Over the last 12 months, Purple Biotech's shares have ranged in value from as little as $0.2198 up to $7.25. A popular way to gauge a stock's volatility is its "beta".

PPBT.US volatility(beta: 2.04)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Biotech's is 2.0372. This would suggest that Purple Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Purple Biotech overview

Purple Biotech Ltd. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site